Quick Answer
SeaStar Medical Holding Corp reported R&D Expense of $7.52 million for fiscal year 2025.
SeaStar Medical Holding Corp R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $7.52M | -17.4% |
| 2024 | $9.11M | +52.4% |
| 2023 | $5.97M | +138.6% |
| 2022 | $2.50M | -9.5% |
| 2021 | $2.77M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.85M | -20.8% | +78.4% |
| June 30, 2025 | $1.04M | -55.6% | -57.3% |
| March 31, 2025 | $2.43M | +43.3% | +4.1% |
| September 30, 2024 | $2.34M | +114.9% | +0.1% |
| June 30, 2024 | $2.33M | +17.8% | +37.5% |
| March 31, 2024 | $1.70M | -1.9% | +56.1% |
| September 30, 2023 | $1.09M | +49.5% | -45.1% |
| June 30, 2023 | $1.98M | +232.4% | +14.5% |
- SeaStar Medical Holding Corp showed a decrease of -17.4% in R&D Expense compared to the prior fiscal year.
- Over the 2021–2025 period, SeaStar Medical Holding Corp’s r&d expense has grown by 171.8% (from $2.77 million to $7.52 million).
- The most recent figure is from SeaStar Medical Holding Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: